Kahn Clare 4
4 · Solid Biosciences Inc. · Filed Dec 15, 2022
Insider Transaction Report
Form 4
Kahn Clare
Director
Transactions
- Award
Director Stock Option (Right to Buy)
2022-12-13+9,650→ 9,650 totalExercise: $6.47Exp: 2032-12-13→ Common Stock (9,650 underlying)
Footnotes (1)
- [F1]This option was granted on December 13, 2022 and vests in full on the one-year anniversary of the grant date, and will vest automatically as to 100% of the unvested portion of such option upon specified change in control events.